Oncocyte CORP 8-K filings
8-K: Oncocyte Corporation Appoints Ekkehard Schtz as Chief Science Officer with New Employment Agreement
Oncocyte Corporation has entered into an employment agreement with Ekkehard Schtz, M.D., Ph.D., appointing him as Chief Science Officer, effective May 20, 2024.
Oncocyte announced its first quarter 2024 financial results, highlighting a new partnership with Bio-Rad, progress in commercializing its GraftAssure test, and a reduction in cash burn.
8-K: Oncocyte Secures $15.8 Million in Private Placement to Bolster Operations and Redeem Preferred Stock
Oncocyte Corporation has successfully raised $15.8 million through a private placement to fund operations and redeem outstanding preferred stock.
Oncocyte Corporation and Bio-Rad Laboratories have entered into a collaboration agreement to commercialize Oncocyte's transplant monitoring assays, with Bio-Rad making an equity investment and gaining global distribution rights.
Oncocyte Corporation has officially launched its VitaGraft Kidney test, a blood-based assay for monitoring kidney transplant patients, making it broadly available after an early access program.